Sonnet biotherapeutics provides fiscal year 2021 third quarter business and earnings update

Sonnet biotherapeutics provides fiscal year 2021 third quarter business and earnings update expanded f h ab intellectual property portfolio  completed $15.9 million at-the-market financing  son-1010 and son-080 on track for ind submissions by calendar year end  princeton, nj / accesswire / august 16, 2021 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended june 30th , 2021 and provided a business update. "throughout the quarter, we've continued to make several advancements towards the clinic with our proprietary fully human albumin binding (f h ab) pipeline assets, and our partnered product" commented pankaj mohan, ph.d.
SONN Ratings Summary
SONN Quant Ranking